Stocks · News reference
Nyxoah's ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints
Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse PatientsReports an Apnea-Hypopnea Index (AHI) responder rate of 77.2% on a Full Analysis Set basis
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cantor Fitzgerald Maintains Overweight on Nyxoah, Lowers Price Target to $6
Cantor Fitzgerald analyst Sarah James maintains Nyxoah (NASDAQ:NYXH) with a Overweight and lowers the price target from $11 to $6.
Piper Sandler Reiterates Overweight on Nyxoah, Lowers Price Target to $6
Piper Sandler analyst Adam Maeder reiterates Nyxoah (NASDAQ:NYXH) with a Overweight and lowers the price target from $7 to $6.